Talis Biomedical Corporation (TLIS)

USD 1.6

(6.67%)

Long Term Debt Summary of Talis Biomedical Corporation

  • Talis Biomedical Corporation's latest annual long term debt in 2023 was 16.78 Million USD , down -43.82% from previous year.
  • Talis Biomedical Corporation's latest quarterly long term debt in 2024 Q2 was 15.87 Million USD , down 0.0% from previous quarter.
  • Talis Biomedical Corporation reported annual long term debt of 29.87 Million USD in 2022, up 134.44% from previous year.
  • Talis Biomedical Corporation reported annual long term debt of 12.74 Million USD in 2021, down 0.0% from previous year.
  • Talis Biomedical Corporation reported quarterly long term debt of 15.87 Million USD for 2024 Q2, down 0.0% from previous quarter.
  • Talis Biomedical Corporation reported quarterly long term debt of 17.64 Million USD for 2023 Q2, up 50.21% from previous quarter.

Annual Long Term Debt Chart of Talis Biomedical Corporation (2023 - 2018)

Historical Annual Long Term Debt of Talis Biomedical Corporation (2023 - 2018)

Year Long Term Debt Long Term Debt Growth
2023 16.78 Million USD -43.82%
2022 29.87 Million USD 134.44%
2021 12.74 Million USD 0.0%
2020 - USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%

Peer Long Term Debt Comparison of Talis Biomedical Corporation

Name Long Term Debt Long Term Debt Difference
Acutus Medical, Inc. 32.65 Million USD 48.594%
Biotricity, Inc. 10.85 Million USD -54.627%
Cell MedX Corp. - USD -Infinity%
Dynatronics Corporation 3.25 Million USD -415.148%
Nemaura Medical Inc. 3.08 Million USD -443.65%
PetVivo Holdings, Inc. 1.01 Million USD -1550.654%
RetinalGenix Technologies Inc. - USD -Infinity%
Sonendo, Inc. 14.03 Million USD -19.601%
Telesis Bio, Inc. 5.26 Million USD -218.58%
Viveve Medical, Inc. 5.12 Million USD -227.596%